Feasibility and Safety Evaluation of Endoscopic Treatment of Esophagogastric Varices in Cirrhosis on the Day-care Unit
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Liver Cirrhosis, Gastroesophageal Varices. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Feasibility and Safety Assessment of Endoscopic Treatment of Esophagogastric Variceal Bleeding in Cirrhosis on the Day Unit: a Single-centre, Prospective-historical Controlled Study
Overview
The goal of this observational study is to learn about the feasibility and safety evaluation of endoscopic treatment of esophagogastric varices in cirrhosis on the day-care ward. The main question it aims to answer is: Is inpatient endoscopic treatment on day wards also feasible and safe for patients with esophagogastric variceal bleeding in cirrhosis when compared to inpatient endoscopy on a general ward? Participants undergoing inpatient endoscopic treatment for cirrhotic esophagogastric variceal bleeding on day wards and general wards will answer online survey questions about their postoperative period over a 1-year period.
Detailed description
Our project team found that for patients with varicose veins treated with re-endoscopy during sequential treatment, day ward treatment can also achieve the goal of eradicating varicose veins, reducing bleeding, and shortening the number of days in the hospital, reducing hospitalization costs, and increasing the satisfaction of the patient's visit. This study was a single-center, prospective-historical controlled study that prospectively included study participants who underwent reendoscopic treatment of cirrhotic esophagogastric varices who presented to the gastroenterology day unit of our hospital from May 2025 to December 2028 and were followed up until the death of the study participant or the end of the study, with a follow-up period of 1 year. Retrospectively included study participants who underwent reendoscopic treatment for cirrhotic esophagogastric varices who presented to the gastroenterology department of our hospital between October 2023 and October 2024, screened study participants as controls according to propensity score matching and a 1:1 ratio, and followed prospectively until the death of the study participants or the end of the study, with a follow-up period of 1 year. The key scientific question of the study was to assess whether re-endoscopic treatment of bleeding esophagogastric varices in cirrhosis on day wards is feasible and safe. The objective of the study was to assess the feasibility and safety of reendoscopic treatment of cirrhotic esophagogastric variceal bleeding on day wards.
Primary outcome measures
- Variceal rebleeding rate at 1-year follow-up after enrollment [Time frame: 1 years]
Secondary outcome measures (5)
- Varicose vein recurrence rate within 1 year of follow-up after enrollment [Time frame: 1 years]
- Mortality Rate Within 1 Year of Follow-Up After Enrollment [Time frame: 1 years]
- Incidence of Overt Hepatic Encephalopathy (HE) Within 1 Year of Follow-Up After Enrollment [Time frame: 1 years]
- Hospitalization Duration [Time frame: 1 years]
- Hospitalization Cost [Time frame: 1 years]
Eligibility criteria
Inclusion criteria
- aged 18-75 years;
- diagnosis of cirrhosis and portal hypertension by clinical manifestations, laboratory tests, imaging tests and histologic examinations;
- gastroscopic grading of esophagogastric varices as moderate or severe;
- no ruptured esophagogastric varices bleeding in the last 5 days;
- endoscopic treatment of esophagogastric varices during hospitalization.
Exclusion criteria
- first endoscopic treatment of esophagogastric varices;
- this is an acute esophagogastric variceal rupture and bleeding;
- previous TIPS or liver transplantation;
- isolated fundal varices or ectopic varices;
- primary hepatocellular carcinoma or acute or chronic hepatic failure, Child-pugh class C, hepatic encephalopathy stage 2 or higher;
- spontaneous abnormally large shunts, uncontrolled infections and sepsis, uncontrolled hypertension;
- combined cardiac, pulmonary, cerebral, renal and other serious complications or other reasons for not being able to tolerate the examination;
- pregnant women and lactating women;
- failure to sign the informed consent or refusal to participate.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07129447 · 20250415-QiluH